Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime ...

The NFL has put its coaching accelerator program designed to bolster diversity efforts on hold. It makes the NFL look weak ...

Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi's M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking ...

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Announce initial clinical data from Cohort 1 in the Phase 1/2 trial of PM359 for p47 phox CGD in 2025. The initial readout ...

Boehringer Ingelheim has entered a multi-year partnership with Tempus AI to progress its cancer treatment pipeline.

Management flagged the importance of mitigating new tariffs, navigating the loss of exclusivity for major products, and sustaining growth from its expanding medicine pipeline. Johnson & Johnson ...

Impaired neuromusculoskeletal function due to conditions such as stroke, osteoarthritis, cerebral palsy, Parkinson's disease, ...

Strategic priorities did not shift markedly, with primary attention on INO-3107's advancement and the next-generation DNA medicine platform. Management acknowledged the evolving nature of tariffs ...

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.